People: Aveo Pharmaceuticals Inc (AVEO.O)

Summary

Name	Age	Since	Current Position
Anthony Evnin	71	2002	Independent Chairman of the Board
Tuan Ha-Ngoc	60	2002	President, Chief Executive Officer, Director
David Johnston	57	2007	Chief Financial Officer
Elan Ezickson	49	2012	Chief Operating Officer, Executive Vice President
Joseph Vittiglio	41	2013	Senior Vice President, General Counsel
Mary Jones	60	2012	Senior Vice President - Human Resources
Jeno Gyuris	53	2012	Chief Scientific Officer
Michael Bailey	47	2010	Chief Commercial Officer
William Slichenmyer	55	2009	Chief Medical Officer
Robert Epstein	57	2012	Director
Kenneth Weg		2002	Director
Kenneth Bate	62	2007	Independent Director
Raju Kucherlapati		2001	Independent Director
Henri Termeer	66	2011	Independent Director
Robert Young	72	2009	Independent Director
Monique Allaire			IR Contact Officer

» Insider Trading

Biographies

Name	Description
Anthony Evnin	Dr. Anthony B. Evnin, Ph.D is Independent Chairman of the Board of AVEO Pharmaceuticals Inc. He has been a Partner at Venrock, a venture capital firm, where he focuses largely on life sciences investments and, in particular, biotechnology investments, since 1975. Dr. Evnin currently serves on the boards of Infinity Pharmaceuticals, Inc. and Pharmos Corporation, both public biopharmaceutical companies, and several private biopharmaceutical companies, including Acceleron Pharma Inc., Constellation Pharmaceuticals, Inc., and Metabolex, Inc. During the last five years, Dr. Evnin served as a director of Altea Therapeutics Corporation, Celladon Corporation, and Syntonix Pharmaceuticals, Inc., all private biopharmaceutical companies, Kenet, Inc. a semiconductor company, and Boston-Power, Inc., a lithium-ion battery company, as well as the following publicly traded biopharmaceutical companies: Memory Pharmaceuticals Corp., Sunesis, Inc., Renovis, Inc., Icagen, Inc. and Coley Pharmaceutical Group. His previous experience was as a manager of business development at Story Chemical Corporation and a research scientist at Union Carbide Corporation. Dr. Evnin is a Trustee of The Rockefeller University and of The Jackson Laboratory, Trustee Emeritus of Princeton University, a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, and a Director of the New York Genome Center. Dr. Evnin holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology and an A.B. from Princeton University.
Tuan Ha-Ngoc	Mr. Tuan Ha-Ngoc is President, Chief Executive Officer, Director of AVEO Pharmaceuticals Inc., since June 2002. From 1999 to 2002, he was co-founder, President and Chief Executive Officer of deNovis, Inc., an enterprise-scale software development company for the automation of healthcare administrative functions. From 1998 to 1999, Mr. Ha-Ngoc was Corporate Vice President of Strategic Development for Wyeth, following Wyeth’s acquisition of Genetics Institute, where Mr. Ha-Ngoc served as Executive Vice President with responsibility for corporate development, commercial operations and European and Japanese operations. Mr. Ha-Ngoc serves on the boards of a number of academic and nonprofit organizations, including the Harvard School of Dental Medicine, the Tufts School of Medicine, and the MIT Koch Institute of Integrative Cancer Research. Mr. Ha-Ngoc served on the Board of Directors of ArQule, Inc., from 2002 until 2006, and Human Genome Sciences, Inc. (now part of GlaxoSmithKline) from 2006 until 2012. He holds an M.B.A. from INSEAD and an M.A. in pharmacy from the University of Paris, France.
David Johnston	Mr. David Johnston is Chief Financial Officer of AVEO Pharmaceuticals Inc., since October 2007. From 1998 to 2007, he served as Senior Vice President of Corporate Finance at Genzyme Corporation. Mr. Johnston sits on the Board of Directors of Tissue Banks International. Mr. Johnston holds a B.S. from Washington and Lee University and an M.B.A. from the University of Michigan.
Elan Ezickson	Mr. Elan Ezickson is Chief Operating Officer, Executive Vice President of AVEO Pharmaceuticals Inc., since February 2012. Mr. Ezickson joined company in April 2003 and served as Chief Business Officer until July 2010 and Executive Vice President, Chief Business Officer from July 2010 to February 2012. From 1994 to 2003, he worked at Biogen in roles that included President of Biogen Canada, Program Executive and Associate General Counsel. Mr. Ezickson holds a B.A. in Political Science from Yale University and a J.D. from the Columbia University School of Law.
Joseph Vittiglio	Mr. Joseph Vittiglio is Senior Vice President, General Counsel of AVEO Pharmaceuticals Inc., since January 24, 2013. Mr. Vittiglio joined AVEO in October 2007 and served as Corporate Counsel until January 2010, as Vice President, Corporate Counsel from January 2010 until January 2012 and Vice President, Chief Corporate Counsel from January 2012 to January 2013. Mr. Vittiglio has over 15 years of experience in corporate and securities law, with a particular focus in the biotech and pharmaceutical industries. Prior to joining AVEO, Mr. Vittiglio was the director of corporate legal affairs of Oscient Pharmaceuticals from 2005 through 2007. From 1998 through 2005, Mr. Vittiglio was an attorney at the Boston law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., where his practice focused principally in the life science and technology industries, working on collaborative arrangements, corporate partnering, registered public securities offerings, mergers and acquisitions and venture financings. Mr. Vittiglio serves on the Board of Directors of two nonprofit organizations, the Casa Monte Cassino in Boston and Lynnfield Youth Soccer. Mr. Vittiglio holds a degree in International Relations from Tufts University and graduated from Northeastern University School of Law in 1996.
Mary Jones	Ms. Mary Ellen Jones has been appointed as Senior Vice President - Human Resources of AVEO Pharmaceuticals Inc. She brings more than 30 years of human resources (HR) and operations experience to the company. Ms. Jones has been a HR leader in multiple industries, and is experienced in establishing HR services for high growth companies with domestic and international locations. Prior to joining AVEO, Ms. Jones served as senior vice president of HR at Verenium. Prior to Verenium, Ms. Jones was an HR executive at several other energy, research and technology companies in addition to several years of HR consulting services to client companies in a variety of industries. Ms. Jones has experience in recruiting and retention, compensation, management coaching and organizational effectiveness and development. She received a B.A. degree from the College of the Holy Cross. She is a former member of the Board of Trustees of the College of the Holy Cross and a current member of its Board of Advisors.
Jeno Gyuris	Dr. Jeno Gyuris, Ph.D., is Chief Scientific Officer of AVEO Pharmaceuticals Inc., since February 2012. He oversees all research activities. Dr. Gyuris joined company in January 2003 and served as Vice President, Molecular Technologies until January 2007, as Senior Vice President, Drug Discovery from January 2007 to January 2010 and Senior Vice President, Head of Research from January 2010 to January 2012. From 1993 to 2002, Dr. Gyuris worked at GPC Biotech AG, formerly Mitotix Inc., where he held positions of increasing responsibility, most recently Vice President of Molecular Technologies. Dr. Gyuris has received several research fellowships in Europe and the United States, and is the author of numerous patents and publications. Dr. Gyuris received his Ph.D. from University of Szeged, Szeged, Hungary.
Michael Bailey	Mr. Michael P. Bailey is Chief Commercial Officer of AVEO Pharmaceuticals Inc., since September 2010. Prior to joining company, Mr. Bailey served as Senior Vice President, Business Development and Chief Commercial Officer at Synta Pharmaceuticals from 2008 to September 2010. From 1999 to 2008, Mr. Bailey worked at ImClone, their commercial organization, most recently as Senior Vice President of Commercial Operations. Prior to his role at ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc. from 1997 to 1999. Mr. Bailey started his career in the pharmaceutical industry as part of Smith-Kline Beecham’s Executive Marketing Development Program, where he held a variety of commercial roles from 1992 to 1997, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the University of Notre Dame Graduate School of Business.
William Slichenmyer	Dr. William Slichenmyer, M.D., Sc.M. is Chief Medical Officer of AVEO Pharmaceuticals Inc., since September 2009. Prior to joining company, Dr. Slichenmyer served as Chief Medical Officer at Merrimack Pharmaceuticals from 2007 to September 2009. From 2000 to 2007, Dr. Slichenmyer worked at Pfizer Inc. in roles that included Vice President and Global Head of Oncology Clinical Development as well as positions in medical affairs and regulatory affairs. Dr. Slichenmyer holds a B.A. and M.D. from Case Western Reserve University and an Sc.M. in clinical investigation from Johns Hopkins University.
Robert Epstein	Dr. Robert S. Epstein, M.D., M.S. has been appointed as Director of AVEO Pharmaceuticals, Inc., effective as of December 18, 2012. Dr. Epstein was most recently president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc. In this role, Dr. Epstein was responsible for launching Medco’s personalized medicine research and programs as well as the Medco Research Consortium, and oversaw all of Medco’s research initiatives in personalized medicine, drug safety, health economics, outcomes, and comparative effectiveness conducted by more than 1,800 researchers worldwide. Dr. Epstein previously served as Medco’s senior vice president and chief medical officer for 13 years. Before joining the private sector, Dr. Epstein was an epidemiologist and held various positions in public health and academia. He is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and has served on the Board of Directors of the Drug Information Association. In 2008, he was elected to the CDC EGAPP Stakeholder Committee and the AHRQ CERT Steering Committee. He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.
Kenneth Weg	Mr. Kenneth E. Weg is Director of AVEO Pharmaceuticals Inc., since January 2002. He has over 34 years of experience in the pharmaceutical industry with global biopharmaceutical companies Bristol-Myers Squibb Company and Merck & Co., Inc. From 1993 to 1998 he was President, Worldwide Medicines Group of Bristol-Myers Squibb Company, responsible for all ethical pharmaceuticals and over-the-counter medicines on a global basis. Mr. Weg also served as Vice-Chairman of the Board. He retired from Bristol-Myers Squibb Company in February 2001. Mr. Weg also served as non-Executive Chairman of Millennium Pharmaceuticals until that company was acquired by Takeda, Inc. in 2007. During the last five years, Mr. Weg has served as a member of the board of directors at Millennium Pharmaceuticals. Mr. Weg was also a founder and the Chairman of Clearview Projects, Inc., a strategic advisory firm, from 2002 to 2010. He is also a founder and chairman of Metamark Genetics. Currently, Mr. Weg serves on the board at Fox Chase Cancer Center. He holds a B.A. in English Literature from Dartmouth College and an M.B.A. from Columbia University.
Kenneth Bate	Mr. Kenneth M. Bate is Independent Director of AVEO Pharmaceuticals Inc since December 2007. He is currently an independent consultant. Previously, Mr. Bate was the President and Chief Executive Officer of Archemix Corp., a privately held biopharmaceutical company, a position he held from April 2009 through December 2011. From 2006 to April 2009, he served in various positions at NitroMed, Inc., a public pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Head of Commercial Operations and Chief Financial Officer at Millennium Pharmaceuticals. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, he was employed with Biogen, Inc. (now Biogen Idec Inc.), a public biotechnology company, first as their Chief Financial Officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. Mr. Bate currently serves as Chairman of the Board of Cubist Pharmaceuticals, Inc., and on the board of BioMarin Pharmaceutical, Inc., each a public biopharmaceutical company. During the last five years, Mr. Bate has served as a director of NitroMed, Archemix, TransMedics, Inc., a privately held medical device company, and Coley Pharmaceutical Group, Inc., a biopharmaceutical company, which was a public company during the period of Mr. Bate’s service. He holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania.
Raju Kucherlapati	Dr. Raju S. Kucherlapati, Ph.D. is Independent Director of AVEO Pharmaceuticals Inc., since October 2001. He has been a professor of Medicine at Harvard Medical School since 2001 and served as Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics from 2001 to 2008. Dr. Kucherlapati was a founder of Cell Genesys, Inc., a biopharmaceutical company, Abgenix, Inc., a life sciences company, and Millennium Pharmaceuticals, and currently serves on the board of Enlight Biosciences LLC, a privately held drug discovery and development technologies company, Metamark Genetics, and Kew Group LLC, a privately held personalized oncology company. During the last five years, Dr. Kucherlapati has served as a member of the board of directors at Millennium Pharmaceuticals and Abgenix. Dr. Kucherlapati holds a B.S. in Biology from P.R. College, Kakinada, India, a M.S. in Biology from Andhra University, Waltair, India and a Ph.D. from the University of Illinois at Urbana.
Henri Termeer	Mr. Henri A. Termeer has been appointed as Independent Director of AVEO Pharmaceuticals, Inc., effective as of April 8, 2011. Mr. Termeer has served as a director since April 2011 and is Chairman of the Board. Prior to June 2011, Mr. Termeer had served as President and a director of Genzyme Corporation, a global public biotechnology company, since October 1983, as Chief Executive Officer since 1985 and as Chairman of the Board since May 1988. Mr. Termeer was co-chairman of the transition committee following the acquisition of Genzyme by Sanofi in April 2011 and resigned from Genzyme in June 2011 following the completion of the initial phase of the integration plan. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors, and he is a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. Mr. Termeer is also Chairman Emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. He served on the board of directors of the Pharmaceutical Research and Manufacturers of America from 1997 to 2011. Mr. Termeer is also a former Chairman of the Federal Reserve Bank of Boston’s board of directors, and a board member of ABIOMED Inc., a public medical device company, Verastem, Inc., a public biopharmaceutical company, and Medical Simulation Corporation, a healthcare industry consulting services provider. He is a board member of Massachusetts Institute of Technology Corporation and serves on its Executive Committee. Mr. Termeer is a director of Massachusetts General Hospital, a board member of Partners HealthCare and a member of the Board of Fellows of Harvard Medical School.
Robert Young	Dr. Robert C. Young, M.D. is Independent Director of AVEO Pharmaceuticals Inc., since July 2009. Dr. Young is President of RCY Medicine, a consulting service focused on cancer center productivity, health care quality and health policy, which he founded in July 2009. From 2007 to 2009 he served as Chancellor of Fox Chase Cancer Center and as President and Chief Executive Officer from 1989 to 2007. Dr. Young is a past-President of the American Society of Clinical Oncology (ASCO), the American Cancer Society and the International Gynecologic Cancer Society and past Chairman of the Board of Scientific Advisors of the National Cancer Institute and is past Chairman of the Comprehensive Cancer Network. Dr. Young serves as Chairman of the editorial board of Oncology Times. He served on the board of directors of West Pharmaceutical Services, Inc., a public pharmaceutical technology company, from July 2002 to May 2012 and currently serves on the board of directors of Human Genome Sciences. During the last five years, Dr. Young has served as a member of the scientific advisory boards of the Dana Farber Cancer Center, the Huntsman Cancer Center and the Ohio State Cancer Center. He holds a B.Sc. in zoology from Ohio State University and an M.D. from Cornell University Medical College and is board certified in Internal Medicine, Hematology and Medical Oncology.
Monique Allaire

Basic Compensation

Name	Fiscal Year Total
Anthony Evnin	--
Tuan Ha-Ngoc	2,027,540
David Johnston	760,932
Elan Ezickson	783,799
Joseph Vittiglio	--
Mary Jones	--
Jeno Gyuris	604,664
Michael Bailey	1,796,910
William Slichenmyer	814,568
Robert Epstein	--
Kenneth Weg	--
Kenneth Bate	--
Raju Kucherlapati	--
Henri Termeer	--
Robert Young	--
Monique Allaire	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Anthony Evnin	0	0
Tuan Ha-Ngoc	28,000	440,940
David Johnston	10,000	114,099
Elan Ezickson	10,000	129,939
Joseph Vittiglio	0	0
Mary Jones	0	0
Jeno Gyuris	75,050	1,047,190
Michael Bailey	0	0
William Slichenmyer	57,000	406,055
Robert Epstein	0	0
Kenneth Weg	0	0
Kenneth Bate	0	0
Raju Kucherlapati	0	0
Henri Termeer	0	0
Robert Young	0	0
Monique Allaire	0	0

Insider Trading

Name	Shares Traded	Price
EVNIN ANTHONY B	1,034	$7.25
TERMEER HENRI A	2,482	$7.25
WEG KENNETH E	1,724	$7.25
YOUNG ROBERT C	844	$7.25
JOHNSTON DAVID BRANNON	1,061	$7.34
TERMEER HENRI A	55,499	$6.73
YOUNG ROBERT C	990	$6.60
EZICKSON ELAN	1,150	$7.77
GYURIS JENO	767	$7.77
VITTIGLIO JOSEPH D	384	$7.77
SLICHENMYER WILLIAM	1,150	$7.77
JOHNSTON DAVID BRANNON	1,150	$7.77
BAILEY MICHAEL P	767	$7.77
JOHNSTON DAVID BRANNON	32,500	$0.00
GYURIS JENO	32,500	$0.00
JONES MARY ELLEN	22,500	$0.00
BAILEY MICHAEL P	42,500	$0.00
VITTIGLIO JOSEPH D	22,500	$0.00
EZICKSON ELAN	37,500	$0.00
HA NGOC TUAN	82,500	$0.00
SLICHENMYER WILLIAM	37,500	$0.00
HA NGOC TUAN	14,100	$6.85
TERMEER HENRI A	5,200	$6.65
YOUNG ROBERT C	2,200	$6.78
YOUNG ROBERT C	171	$6.78

» Full list on Insider Trading

People: Aveo Pharmaceuticals Inc (AVEO.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: